BR112015002601A2 - derivados de (aza-)isoquinolinona. - Google Patents

derivados de (aza-)isoquinolinona.

Info

Publication number
BR112015002601A2
BR112015002601A2 BR112015002601A BR112015002601A BR112015002601A2 BR 112015002601 A2 BR112015002601 A2 BR 112015002601A2 BR 112015002601 A BR112015002601 A BR 112015002601A BR 112015002601 A BR112015002601 A BR 112015002601A BR 112015002601 A2 BR112015002601 A2 BR 112015002601A2
Authority
BR
Brazil
Prior art keywords
aza
isoquinolinone derivatives
isoquinolinone
derivatives
Prior art date
Application number
BR112015002601A
Other languages
English (en)
Inventor
Dorsch Dieter
Buchstaller Hans-Peter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112015002601A2 publication Critical patent/BR112015002601A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
BR112015002601A 2012-08-08 2013-07-12 derivados de (aza-)isoquinolinona. BR112015002601A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12005752 2012-08-08
PCT/EP2013/002085 WO2014023390A2 (en) 2012-08-08 2013-07-12 (aza-)isoquinolinone derivatives

Publications (1)

Publication Number Publication Date
BR112015002601A2 true BR112015002601A2 (pt) 2017-07-04

Family

ID=48793165

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015002601A BR112015002601A2 (pt) 2012-08-08 2013-07-12 derivados de (aza-)isoquinolinona.

Country Status (24)

Country Link
US (1) US9376433B2 (pt)
EP (1) EP2882714B1 (pt)
JP (2) JP6247294B2 (pt)
KR (1) KR102083154B1 (pt)
CN (1) CN104507912B (pt)
AR (1) AR092366A1 (pt)
AU (1) AU2013301870B2 (pt)
BR (1) BR112015002601A2 (pt)
CA (1) CA2881330C (pt)
DK (1) DK2882714T3 (pt)
ES (1) ES2773272T3 (pt)
HK (1) HK1209106A1 (pt)
HR (1) HRP20200180T1 (pt)
HU (1) HUE047608T2 (pt)
IL (1) IL237072B (pt)
LT (1) LT2882714T (pt)
MX (1) MX362939B (pt)
PL (1) PL2882714T3 (pt)
PT (1) PT2882714T (pt)
RS (1) RS59921B1 (pt)
RU (1) RU2654216C2 (pt)
SG (1) SG11201500732TA (pt)
SI (1) SI2882714T1 (pt)
WO (1) WO2014023390A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9193689B2 (en) 2012-03-07 2015-11-24 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
WO2014087165A1 (en) * 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors
NO3044221T3 (pt) 2013-09-11 2018-07-21
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
JP6359175B2 (ja) 2014-04-10 2018-07-18 フーベイ バイオ−ファーマシューティカル インダストリアル テクノロジカル インスティテュート インコーポレイテッド PARP阻害剤としての4H‐ピラゾロ[1,5‐α]ベンゾイミダゾール化合物のアナログ
CN105153156B (zh) * 2015-09-22 2017-07-28 徐峰 一种4‑苯基‑2,7‑萘啶‑1(2h)‑酮的制备方法
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
US10759795B2 (en) 2016-03-15 2020-09-01 Purdue Research Foundation Aza-A-ring indenoisoquinoline topoisomerase I poisons
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
JP7182548B2 (ja) 2016-12-22 2022-12-02 パードゥ リサーチ ファウンデーション アザインデノイソキノリン化合物およびその使用
US10899733B2 (en) 2017-08-23 2021-01-26 Oregon Health & Science University Inhibitors of PARPs that catalyze mono-ADP-ribosylation
RU2709928C1 (ru) * 2019-02-21 2019-12-24 Федеральное государственное бюджетное научное учреждение "Институт природно-технических систем" (ИПТС) Датчик удельной электропроводности
WO2024029583A1 (ja) * 2022-08-05 2024-02-08 国立研究開発法人理化学研究所 新規ピラゾール誘導体及びその用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CZ291386B6 (cs) 1996-02-13 2003-02-12 Zeneca Limited Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
WO1999011622A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
WO1999018077A1 (fr) 1997-10-02 1999-04-15 Eisai Co., Ltd. Derives de pyridine condenses
JP3989102B2 (ja) * 1997-10-02 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリジン誘導体
EE200100085A (et) * 1998-08-11 2002-08-15 Pfizer Products Inc. Asendatud 1,8-naftüridiin-4(1H)-oonid kui fosfodiesteraas 4 inhibiitorid
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
EP1301497A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2005075432A1 (ja) * 2004-02-06 2005-08-18 Chugai Seiyaku Kabushiki Kaisha 1−(2h)−イソキノロン誘導体およびその抗ガン剤としての使用
US7772180B2 (en) * 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK2118074T3 (en) * 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
ES2381446T3 (es) 2007-03-08 2012-05-28 Janssen Pharmaceutica, N.V. Derivado de quinolinona como inhibidores de PARP y TANK
TWI499418B (zh) 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉-1(2h)-酮衍生物
FR2956816B1 (fr) 2010-03-01 2012-05-18 Univ Joseph Fourier Utilisation de quinolones pour la preparation de medicaments, nouvelles quinolones et leur procede de synthese
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9193689B2 (en) * 2012-03-07 2015-11-24 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US20130311482A1 (en) 2012-05-17 2013-11-21 Tagged, Inc. Multi-user timeline for facilitating social discovery in social networking environments

Also Published As

Publication number Publication date
PT2882714T (pt) 2020-02-19
US9376433B2 (en) 2016-06-28
AR092366A1 (es) 2015-04-15
CN104507912A (zh) 2015-04-08
DK2882714T3 (da) 2020-01-20
EP2882714A2 (en) 2015-06-17
WO2014023390A3 (en) 2014-04-10
HK1209106A1 (en) 2016-03-24
RU2015107702A (ru) 2016-09-27
EP2882714B1 (en) 2019-11-13
IL237072B (en) 2018-11-29
MX362939B (es) 2019-02-27
SI2882714T1 (sl) 2020-03-31
MX2015001545A (es) 2015-05-11
KR102083154B1 (ko) 2020-03-02
JP6247294B2 (ja) 2017-12-13
JP2018008974A (ja) 2018-01-18
HRP20200180T1 (hr) 2020-05-01
JP2015524450A (ja) 2015-08-24
US20150210686A1 (en) 2015-07-30
AU2013301870A1 (en) 2015-03-19
AU2013301870B2 (en) 2017-04-27
RU2654216C2 (ru) 2018-05-17
JP6333450B2 (ja) 2018-05-30
PL2882714T3 (pl) 2020-02-28
CN104507912B (zh) 2016-09-28
HUE047608T2 (hu) 2020-05-28
SG11201500732TA (en) 2015-02-27
WO2014023390A2 (en) 2014-02-13
CA2881330C (en) 2020-07-21
RS59921B1 (sr) 2020-03-31
KR20150041649A (ko) 2015-04-16
LT2882714T (lt) 2020-03-10
ES2773272T3 (es) 2020-07-10
CA2881330A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
FR22C1047I2 (fr) Derives de benzimidazole-proline
BR112015002601A2 (pt) derivados de (aza-)isoquinolinona.
CO7010838A2 (es) Compuestos de imidazopirrolidinona
BR112014033077A2 (pt) combinação de vacina.
DK3187586T3 (da) Inducerbar co-ekspressionssystem
BR112014032111A2 (pt) unidade de digestão.
CO7020919A2 (es) Derivados de tetrahidro-quinazolinona
BR112015003022A2 (pt) vestuário de suporte pélvico-abdominal
BR112014022506A2 (pt) variantes de cbh1a
BR112014031026A2 (pt) variantes de beta-xilosidase fúngica.
FR2986872B1 (fr) .
BR112015001416A2 (pt) plugue.
CO7020920A2 (es) Derivado de fenilazol sustituido
ITTO20130048A1 (it) Motociclo.
BR112014027645A2 (pt) 5-halogenopirazol bifenilcarboxamidas.
FR3000112B1 (fr) Structure de securite.
FR2992527B3 (fr) Sous-vetement de securite
BR112015003217A2 (pt) novos derivados de piridina.
FR2994990B1 (fr) Volet de desenfumage
BR112013019806A2 (pt) derivado de tetrahidroisoquinolina.
ES2397885B1 (es) Derivados de colismicina.
ES1077890Y (es) Plantilla de patronaje.
FR2990870B1 (fr) Autoinjecteur.
FR2991803B1 (fr) Detecteur de fumee.
ES1078331Y (es) Pieza de reposteria decorable

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements